The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of lisocabtagene maraleucel for treating large B-cell lymphoma after at least 2 therapies.
Please note that following on from communications with the company , the timelines for this appraisal have now been confirmed.
The appraisal is anticipated to begin during late July 2020 when we will write to you about how you can get involved.